不用本金就能赚钱的方法

来宝网Logo

热门词:生物显微镜 水质分析仪 微波消解 荧光定量PCR 电化学工作站 生物安全柜

现在位置不用本金就能赚钱的方法>技术资料不用本金就能赚钱的方法>行业动态>行业动态>CARMELINA?老年人群亚组分析支持利格列汀用于治疗老年2型糖尿病患者的长期心血管和肾脏安全性

CARMELINA?老年人群亚组分析支持利格列汀用于治疗老年2型糖尿病患者的长期心血管和肾脏安全性

美通社2020年2月13日 3:41 点击:665

勃林格殷格翰宣布,CARMELINA试验的亚组分析结果表明,与安慰剂相比,利格列汀不增加老年2型糖尿病患者的心血管不良事件或低血糖风险。


德国殷格翰2020年2月13日 /美通社/ -- 勃林格殷格翰宣布,CARMELINA®试验的亚组分析结果表明,与安慰剂相比,利格列汀不增加老年2型糖尿病患者的心血管不良事件或低血糖风险。[1] 试验结果已在期刊Diabetes Obesity and Metabolism上发表。


不用本金就能赚钱的方法RENKOULAOLINGHUASHIDETANGNIAOBINGDELIUXINGBINGXUEZHUANXIANGGAOLING。[1] MUQIAN,ZAIGUJIDE4.63YITANGNIAOBINGHUANZHEZHONG,YOUDAYUE1.36YIHUANZHEDENIANLINGZAI65SUIYISHANG。[2] RANER,JINGUANLAONIANTANGNIAOBINGHUANZHEZHANJUJIAODABILI,ZAIJIANGTANGYAOWUDELINCHUANGSHIYANZHONG,LAONIANHUANZHEBINGWEICHONGFENBEINARUYANJIUZHONG。[3]

近期的CARMELINA® 心血管结局试验入组了年龄在18岁及以上的患者,且没有设定最大年龄限制 [4]。预先设定的CARMELINA®亚组分析评价了临床结局和不良事件,并将主要试验结果按照如下预先设定的年龄段进行分组:<65岁、65岁至75岁和≥75岁。[1]

不用本金就能赚钱的方法 “GAIYAZUFENXIGUANZHULELAONIAN2XINGTANGNIAOBINGHUANZHEQUN。ZHEIXIELAONIANHUANZHEKENENGHENCUIRUO、GONGBINGLVJIAOGAO,BINGQIEKENENGJIESHOUDUOZHONGYAOWUZHILIAO,ZHEIXIEDOUDUIQIXUETANGGUANLIGOUCHENGLETIAOZHAN。”BOLINGEYINGEHANGONGSIFUZONGCAI、XINXUEGUANDAIXIELINGYUYIXUEFUZERENWaheed Jamal, MDSHUODAO。“YOUYUZAISUOYOUNIANLINGZUZHONG,LAONIANRENDE2XINGTANGNIAOBINGHUANBINGLVZUIGAO,GAIFENXIDUIYUBANGZHULINCHUANGYISHENGGUANLILAONIANHUANZHEDEZHILIAOLAISHUOYOUZHEBUKEGULIANGDEJIAZHI,ERZAICIQIANDELINCHUANGYANJIUZHONGLAONIANHUANZHEBINGWEIBEICHONGFENYANJIU。”

在各年龄组中,与安慰剂相比,利格列汀不增加肾脏不良事件、动脉粥样硬化性心血管事件或因心力衰竭而住院的风险。[1]不良事件的发生率,包括低血糖,随着年龄增长而升高;但是尽管利格列汀组中HbA1c降低,利格列汀和安慰剂组中的不良事件的发生率相似。1不用本金就能赚钱的方法在所有的年龄组中,与安慰剂相比,利格列汀均改善了血糖控制。[1]

 “高龄以及确诊的心血管和/或肾脏疾病,意味着CARMELINA®试验中的老年患者群是由高风险2型糖尿病患者组成的。”Jamal博士继续说道。“试验结果应该可以让医疗专业人员相信利格列汀适用于广泛的患者群,以改善血糖控制,同时确保心血管和肾脏安全。”

关于CARMELINA®

不用本金就能赚钱的方法CARMELINA®SHIYANSHIYIXIANGDUOGUO、SUIJI、SHUANGMANG、ANWEIJIDUIZHAODELINCHUANGSHIYAN,RUZULAIZI27GEGUOJIA600DUOGESHIYANDIANDE6979MINGCHENGREN2XINGTANGNIAOBINGHUANZHE,YANJIUGUANCHADEZHONGWEISHIJIANWEI2.2NIAN。[4,5]GAIYANJIUZHIZAIPINGGULIGELIETING(5 mg,MEIRIYICI)YUANWEIJI(JUNTIANJIAYUBIAOZHUNZHILIAOFANGFAZHISHANG)DUIYUGAOXUEGUANFENGXIANDE2XINGTANGNIAOBINGHUANZHEXINXUEGUANJIEJUDEYINGXIANG,QIZHONGDADUOSHUHUANZHETONGSHIHUANYOUSHENZANGJIBING。[4,5] GAIHUANZHEQUNWEIYISHENGRICHANGXINGYISHICHANGJIANDEJUYOUGAOXINXUEGUANHE/HUOSHENBINGFENGXIANDEHUANZHE。[6] BIAOZHUNZHILIAOFANGFABAOKUOJIANGTANGYAOWUHEXINXUEGUANYAOWU(BAOKUOKANGGAOXUEYAYAOHEJIANGZHIYAO)DENG。

CARMELINA® 试验由学术试验指导委员会以及由勃林格殷格翰和礼来组成的糖尿病联盟共同发起。与其他针对2型糖尿病患者的二肽基肽酶-4(DPP-4)抑制剂近期发布的结局试验相比,CARMELINA试验纳入的肾功能受损患者比例最大。[7]*[*]

了解更多关于CARMELINA®不用本金就能赚钱的方法的信息,请访问:   

关于欧唐宁®(利格列汀)

欧唐宁®是一种单次给药、每日一次DPP-4抑制剂,能够有效降低成人2型糖尿病患者的血糖水平。可为成人2型糖尿病患者使用欧唐宁,而无需考虑其年龄、病程、种族、体重指数(BMI)、肝功能和肾功能。[8] 在目前全球上市的DPP-4抑制剂中,欧唐宁的经肾脏排泄比例最低。[9-12]

LIGELIETINGYOUBOLINGEYINGEHANHELILAILIANMENGYANFAHESHANGYEHUA。

关于我的心血管试验

YOUYUXINXUEGUANJIBINGSHI2XINGTANGNIAOBINGDEZHUYAOBINGFAZHENGHESHOUYAOSIWANGYUANYIN,YINCIXINXUEGUANJIEJUSHIYANJUYOUGAODUDEXIANGGUANXING。ZAIQUANQIUFANWEINEI,DADUOSHU2XINGTANGNIAOBINGHUANZHESIYUXINXUEGUANSHIJIAN。[13] 2015NIAN,BOLINGEYINGEHANHELILAIGONGTONGXUANBULEBIAOZHIXINGXINXUEGUANJIEJUSHIYANEMPA-REG OUTCOME®DEYANJIUJIEGUO,GAISHIYANDEYANJIUDUIXIANGWEINA-PUTAOTANGXIETONGZHUANYUNDANBAI2(SGLT2)YIZHIJIENGELIEJING。ZAIBIAOZHUNZHILIAOFANGFAZHISHANGSHIYONGENGELIEJING,ZAIQUEZHENHUANZHEXINXUEGUANJIBINGDE2XINGTANGNIAOBINGCHENGRENHUANZHEZHONG,XINXUEGUANSIWANGDEXIANGDUIFENGXIANXIAJIANGLE38%。[†][‡][14–16]ZAIHENDUOGUOJIADESHUOMINGSHUZHONG,ENGELIEJINGSHISHOUGEJUYOUXINXUEGUANSHIYINGZHENGHUOJUYOUXINXUEGUANSIWANGFENGXIANJIANGDISHUJUDEKOUFU2XINGTANGNIAOBINGYAOWU。[14,15]

CAROLINA®是DPP-4抑制剂利格列汀的两项心血管结局试验之一。[17,18] CAROLINA® 和使用利格列汀治疗具有高血管风险的2型糖尿病患者的血管安全与肾脏微血管结局试验(CARMELINA®)[4,5]提供了关于DPP-4抑制剂长期安全性的最全面的数据集。

CARMELINA®是一项多国、随机、双盲、安慰剂对照的临床试验,入组来自27个国家600多个试验点的6979名成人2型糖尿病患者,研究观察的中位时间为2.2年。[4,5] CARMELINA®研究了欧唐宁(利格列汀)对高心血管疾病和/或高肾脏疾病风险2型糖尿病患者的心血管和肾脏安全性的影响。[4,5] 该试验达到了主要终点,[§]与安慰剂相比,在标准治疗方法之上添加利格列汀显示出了相似的心血管安全性特征。[5] CARMELINA®还纳入了一个次要复合终点,[**]与安慰剂相比显示出了相似的肾脏安全性特征。[5] CARMELINA®中利格列汀的总体安全性特征与此前的数据一致,且未观察到新的安全性信号。[5,6] CARMELINA®还表明,接受利格列汀治疗的患者因心力衰竭住院的比率与安慰剂相似。[5]

了解更多关于CAROLINA® 和CARMELINA®的信息,请访问:。

关于勃林格殷格翰

YANFAQUDONGDEZHIYAOGONGSIBOLINGEYINGEHANSHIZHONGZHILIYUGAISHANRENLEIYUDONGWUDEJIANKANG,ZHUANZHUYUTANSUOSHANGWEICHUXIANYOUXIAOZHILIAOFANGANDEJIBINGLINGYU。GONGSIZHELIKAIFACHUANGXINLIAOFA,BANGZHUHUANZHEYANZHANGSHENGMING。ZAIDONGWUBAOJIANLINGYU,BOLINGEYINGEHANDAIBIAOZHEXIANJINDEYUFANGFANGAN。

BOLINGEYINGEHANCHENGLIYU1885NIAN,ZHIJINRENGSHIJIAZUQIYE。GONGSISHIQUANQIUQIAN20DAZHIYAOQIYEZHIYI。ZAIRENYONGYAOPIN、DONGWUBAOJIANHESHENGWUZHIYAOHETONGSHENGCHANSANGEYEWULINGYU,QUANQIUYUE5WANMINGYUANGONGMEITIANDOUZAINULITONGGUOCHUANGXINZHANXIANJIAZHI。2018NIAN,BOLINGEYINGEHANGONGSISHIXIANJINGXIAOSHOUEYUE175YIOUYUAN;YANFAZHICHUJIN32YIOUYUAN,XIANGDANGYUJINGXIAOSHOUEDE18.1%。

ZUOWEIYIJIAJIAZUQIYE,BOLINGEYINGEHANZHICUNGAOYUANBINGZHILIYUHUODEZHANGQIDECHENGGONG。GONGSIZHIZAITONGGUOZISHENZIYUANSHIXIANYOUJIZENGZHANG,TONGSHIJIJIXUNQIUYANFALINGYUDEHEZUOHUOBANYUZHANLVELIANMENG。CIWAI,GONGSIDEYIQIEXINGWEIDOUDUIRENLEIHEHUANJINGFUZE。

不用本金就能赚钱的方法QINGDIANJIGONGSIGUANFANGWANGZHANHUONIANBAO LEJIEGENGDUOGUANYUBOLINGEYINGEHANDEXINXI。

目标读者

BENXINWENGAOYOUWEIYUDEGUOYINGEHANDEBOLINGEYINGEHANGONGSIZONGBUFABU,ZHIZAITIGONGQUANQIUYEWUXINXI。QINGZHUYI,YOUYUHUOPICHANPINDEPIZHUNZHUANGTAIHESHUOMINGSHUDEXIANGGUANXINXIKENENGYINGUOJIAERYI,BOLINGEYINGEHANGONGSIHELILAIGONGSIKAIZHANYEWUDEGUOJIAKENENGYIJINGFABULEZHENDUIGAIZHUTIDEXINWENGAO。

脚注:

 ‘*肾小球滤过率低于60 mL/min/1.73 m2

不用本金就能赚钱的方法患有冠状动脉疾病、外周动脉疾病或有MI或卒中病史的2型糖尿病成年患者

不用本金就能赚钱的方法标准治疗包括医生决定开处的心血管药物和降糖药物

§不用本金就能赚钱的方法主要终点定义为至首次发生3P-MACE(心血管死亡、非致死性心肌梗塞或非致死性卒中)的时间

不用本金就能赚钱的方法**CIYAOZHONGDIANDINGYIWEIZHISHOUCIFASHENGCHIXUDEZHONGMOQISHENZANGBING(ESKD)、SHENBINGYINQIDESIWANGHUOYUANWEIJIXIANGBIeGFRZIJIXIAN≥40%CHIXUJIANGDIDESHIJIAN

REFERENCES:

1.  Cooper M, Rosenstock J, Kadowaki T, et al. Cardiovascular and kidney outcomes of linagliptin treatment in older people with type 2 diabetes and established cardiovascular disease and/or kidney disease: A prespecified subgroup analysis of the randomized, placebo-controlled CARMELINA® trial. Diabetes Obes Metab. 2020; doi: 10.1111/dom.13995.

2.  IDF Diabetes Atlas, 9th edition. Brussels, Belgium: International Diabetes Federation; 2019. Available at: . Accessed: January 2020.

3.  Lakey WC, Barnard K, Batch BC, et al. Are current clinical trials in diabetes addressing important issues in diabetes care? Diabetologia. 2013;56:1226–35.

4.  ClinicalTrials.Gov. Cardiovascular and renal microvascular outcome study with linagliptin in patients with type 2 diabetes mellitus (CARMELINA). Available at: . Accessed: January 2020.

5.  Rosenstock J, Perkovic V, Johansen O, et al. Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk: The CARMELINA Randomized Clinical Trial. JAMA. 2019;321(1):69–79.

6.  Boehringer Ingelheim and Eli Lilly and Company. Data on file.

7.  Rosenstock J, Perkovic V, Alexander JH, et al. Rationale, design, and baseline characteristics of the CArdiovascular safety and Renal Microvascular outcomE study with LINAgliptin (CARMELINA®): a randomized, double-blind, placebo-controlled clinical trial in patients with type 2 diabetes and high cardio-renal risk. Cardiovasc Diabetol. 2018;17(1):39.

8.  European Medicines Agency. Trajenta® (linagliptin) tablets. EMA Summary of Product Characteristics. Available at: . Last updated December 2019. Accessed: January 2020.

9.  European Medicines Agency. Onglyza® (saxagliptin) tablets. EMA Summary of Product Characteristics. Available at: . Last updated: November 2018. Accessed: January 2020.

10.  European Medicines Agency. Vipidia® (alogliptin) tablets. EMA Summary of Product Characteristics. Available at: . Last updated: December 2018. Accessed: January 2020.

11.  European Medicines Agency. Januvia® (sitagliptin) tablets. EMA Summary of Product Characteristics. Available at: . Last updated: April 2019. Accessed: January 2020.

12.  European Medicines Agency. Galvus® (vildagliptin) tablets. EMA Summary of Product Characteristics. Available at: . Last updated: May 2018. Accessed: January 2020.

13.  World Heart Federation. Cardiovascular Disease Risk Factors. Available at: . Accessed: January 2020.

14.  Jardiance® (empagliflozin) tablets U.S. Prescribing Information. FDA. Available at: . Last updated: December 2016. Accessed: January 2020.

15.  Jardiance® (empagliflozin) EMA Summary of Product Characteristics. Available at: . Last updated: January 2020. Accessed: January 2020.

16.  Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med. 2015;373(22):2117–28.

17.  ClinicalTrials.Gov. CAROLINA: Cardiovascular outcome study of linagliptin versus glimepiride in patients with type 2 diabetes. Available at: . Accessed: January 2020.

18.  Marx N, Rosenstock J, Kahn S, et al. Design and baseline characteristics of the CARdiovascular Outcome Trial of LINAgliptin Versus Glimepiride in Type 2 Diabetes (CAROLINA®). Diab Vasc Dis Res. 2015;12不用本金就能赚钱的方法(3):164–74.

 

消息来源:勃林格殷格翰


(来源: 美通社


全年征稿 / 资讯合作

联系邮箱:kefu@strauss-usa.com不用本金就能赚钱的方法

BANQUANYUMIANZESHENGMING

  • 凡本网注明“来源:来宝网”的所有作品,版权均属于来宝网,转载请必须注明来宝网, http://strauss-usa.com,违反者本网将追究相关法律责任。
  • 本网转载并注明自其它来源的作品,目的在于传递更多信息,并不代表本网赞同其观点或证实其内容的真实性,不承担此类作品侵权行为的直接责任及连带责任。其他媒体、网站或个人从本网转载时,必须保留本网注明的作品来源,并自负版权等法律责任。
  • 如涉及作品内容、版权等问题,请在作品发表之日起一周内与本网联系,否则视为放弃相关权利。


湖南快乐十分 湖南快乐十分 福建快3走势图0 福建快3走势图 河南快3走势图 河南快3走势图 广东11选5开奖结果 福建11选5走势图